home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Passive Immunotherapy Against Hepatitis C

  December, 13 2007 10:36
your information resource in human molecular genetics

Delivering antibodies that recognize the hepatitis C virus (HCV) can be therapeutically beneficial in a mouse model, according to a Brief Communication in Nature Medicine.

A major problem in developing vaccines for HCV is the extreme variability of the virus. One idea has been to inject antibodies that work against the virus - what is referred to as 'passive immunotherapy' - hoping that it will reveal if antibodies can protect against infection. Dennis Burton and colleagues identify human antibodies that neutralize in vitro genetically diverse strains of HCV. Furthermore, the authors show that, if they inject the antibodies into mice carrying human liver cells, these 'humanized' mice are protected from HCV infection.

The finding that neutralizing human antibodies protect against viral infection provides proof of principle for the viability of passive immunotherapy against HCV, and raises hopes that it will reveal if antibodies can protect against infection.

Author contact:

Dennis Burton (Scripps Research Institute, La Jolla, CA, USA)
E-mail: burton@scripps.edu

Abstract available online.

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.